Technical Field

The invention relates to a method for obtaining solid plasma which is a completely organic filling material composed of individual’s own blood cells and plasma instead of chemical filling materials used in medical aesthetics.

State of the Art

Aesthetics surgery is a surgical branch that is activated in cases where people can be born with some congenital body anomalies or when a condition like illness, accident, old age can cause disruption in their body shape. Aesthetics surgery also known as plactic surgery is a branch of medicine that repairs tissue and organ disorders in different parts of the body. In plastic surgery operations, tissues are reshaped according to the current disorder and the person is tried to be given the best appearance.

Nowadays, aesthetic surgery has made significant progress in applying anti-aging treatments to individuals. Disorders in facial contours and body shapes that people face due to some genetic features or aging can be solved with many different treatment methods with developing technology. The important point in the treatment methods is to give the most natural and healthy appearance to the person.

The face and neck area is the most important regions where medical aesthetic applications are most commonly applied in the human body. Problems such as sagging, wrinkles, distortion of the V-shape of the face, under eye problems, mimic lines are solved by organic fillings injected into the problematic chamber without distorting the shape of the face and neck. The fillings are divided into three as permanent fillings, semi-permanent fillings and non-permanent fillings. Permanent fillings remain in the body for life and are used for rejuvenation as well as deformities caused by deformation. Efficacy time of the semi-permanent fillers vary between 3-5 years. The most preferred filling applications are non-permanent filling applications. The most preferred one in non-permanent fillers is actually a polysaccharide sugar chain (NASHA) known as hyaluronic acid. It is found naturally in human body. The function of the hyaluronic acis naturally present in tissues is to carry and fix the water into the skin The acid, which is synthetic or animal origin, can be easily accepted by the body. This substance has functions such as cell division, providing the slipperiness of the joints and giving tension to the skin. Hyaluronic acid can retain a thousand times more water than its own volume and maintain its shape for a long time where it is injected. It is produced under special laboratory conditions and presented to cosmetic applications. It is metabolized and excreted by the body in an average of 6-12 months. However, Hyaluronic acid, which is used in the present art, is actually a chemical filler and since it is obtained from chemicals, it can lead to very severe complications and allergies that take 48 hours after application to the human body and regions thereof (lips, cheeks, under eyes, etc.). Also, very high material costs are paid for the amount of 1 ml of Hyaluronic acid, which consists of the mentioned chemical substances, according to the region to be applied.

Patent application TR 2006/02727 belonging to the state of art relates to the removal of fibroblasts, which are a human skin cell, from individuals and culturing thereof in a laboratory environment (autologous cultured fibroblasts) and back injection of the product prepared by placing these cells in a carrier medium consisting of hyaluronic acid, which is also an existing substance in human skin for solving the problems emerging as a result of treatment or aging process in health industry. However in said application cultured fibroblasts are injected into the human body together with hyaluronic acid and it does not solve the problem of usage with chemicals.

In another patent application TR 2015/13883 belonging to the state of art, this invention relates to activation and purification in prp (platalet rich plasma) process which is required for treatment (mostly used in physiotherapy, orthopedics, plastic surgery, skin, hair transplantation) method which is developed for medical usage and used in the regions where cell renewal is desired. This invention discloses obtaining a product which is ready to use as a filling material although it does not solve the problem of dissociating the plasma and blood cells effectively during prp (platalet rich plasma) process.

Purpose of the Invention

Purpose of the invention is to perform a method of obtaining a solid plasma which provides that instead of chemical substances such as hyaluronic acid, solid plasma completely obtained from human blood is used as filling material applied for the purposes of anti-aging in the medical aesthetics field and for restoring the shape of the face as a result of the deformation formed on the face.

Another purpose of the invention is to perform a method of obtaining solid plasma solving the problems of whole complication and non-adaptation that may arise as a result of obtaining the filling material to be injected into the body of the user from the human’s own blood.

Another purpose of the invention is to perform a method of obtaining solid plasma enabling the usage of the filling material as solid plasma preventing the cases which lead to a variety of complications and allergy lasting 48 hours which may arise as a result of using chemical substances such as hyaluronic acid as filling material.

Another purpose of the invention is to eliminate high costs paid for the amount of 1 ml of the chemical filling materials used according to the application area.

Another object of the invention is to perform a method of obtaining solid plasma which will enable the usage of the materials to be used as medical aesthetics material not only to the face and neck region but also to the remaining parts of the body by means of the developing technology.

Description of Drawings

Figure 1 . is a schematic view of the method phases of obtaining the inventive solid plasma and devices used.

Figure 2. is a schematic view of the process steps of the method of obtaining the inventive solid plasma.

Description of the part references

1.Glass blood collection tube

2. Blood sample

3. Plasma

4. Thrombocyte

5. Filter

6.Red blood cells

7. Leukocytes

8. Incubation device

9. Solid plasma filling

100. Method of obtaining solid plasma

101. subjecting a blood sample (2) taken into the glass blood collection tube (1 ) to the dissociation process by centrifugation

102. upon the dissociation process, dissociating a plasma (3) and thrombocyte (4) from red blood cells (6) and leukocytes (7) by means of polyester micro filter (5)

103.destroying the remaining glass blood collection tube (1 ) together with dissociated red blood cells (6) and leukocytes (7) 104. placing the dissociatied plasma (3) and thrombocyte (4) in the incubation device (8) by mixing, holding it at the determined temperature and time intervals and holding it until the time expires

105. at the end of the period, obtaining the solid plasma filling (9)

Drawings are not necessarily drawn according to the scale and details which are not necessary for the understanding of the present invention might be omitted. Additionally, at least significantly identical elements or elements having at least significantly identical functions are shown with the same reference number.

Detailed Description of the Invention

In this detailed description, prefered embodiments of the invention will be only disclosed for the better understanding of the subject and without forming any limiting effect.

The invention is a method of obtaining solid plasma which is completely obtained from human blood instead of chemical substances for using as filling material applied for the purposes of anti-aging in the medical aesthetics field and for restoring the shape of the face as a result of the deformation formed on the face.

Inventive method of obtaining solid plasma (100) comprises the following process steps:

- subjecting a blood sample (2) taken into the glass blood collection tube (1 ) to the dissociation process by centrifugation (101 ),

- upon the dissociation process, dissociating a plasma (3) and thrombocyte (4) from red blood cells (6) and leukocytes (7) by means of polyester micro filter (5) (102),

- destroying the remaining glass blood collection tube (1 ) together with the dissociated red blood cells (6) and leukocytes (7) (103),

- placing the separated plasma (3) and platelet (4) into the incubation device (8) by mixing and holding at determined temperature intervals and holding it until the time expires (104),

- at the end of the period, obtaining the solid plasma filling (9) (105).

The blood sample (2) consists of cells (6) and a fluid called plasma (3). Cells (erythrocytes) (red blood cells) (6) are the leukocytes (white blood cells) (7) and the platelets (4). Red blood cells (6) make up more than 99% of the cells. Red blood cells (6) are oxygen-carrying cells of the blood. Leukocytes (7) are cells that protect the body against infections and cancer. Platelets (4) take part in blood clotting. The blood sample (2) placed in the glass blood collection tube (1 ) is centrifuged and the red blood cells (6) and leukocytes (7) are dissociated from the plasma (3) and platelets (4). Since the red blood cells (6) and leukocytes (7) are heavier, while they deposit in the bottom, the lighter thrombocyte (4) and plasma (3) remain on top.

Plasma (3) is the liquid part of the blood sample (2), it consists of a large number of organic and inorganic substances dissolved in water. The most important of these substances are proteins. Proteins make up about 7% of the total weight of the plasma. Plasma proteins are divided into three main groups. These are albumin, globulins and fibrinogen. The proteins and useful cells in the plasma are directly effective in gaining the healthy tissues and elasticity that the human body loses with aging.

The blood sample (2) is centrifuged at 1 100 RPM for 9 minutes (1 ) in small glass blood collection tubes called "micro pipette" inside of which is plastered with heparin. At the bottom of these said glass blood collection tubes (1 ), erythrocytes, that is, red blood cells (6), are collected, at the top of this leukocytes (7) and platelets (4) in the form of a very thin layer are present, at the uppermost clear straw yellow-white liquid called plasma (3) is collected

By means of the filter (5), the cells required for the solid plasma are filtered by performing dissociation process to the whole blood sample (2). At the end of the centrifugation process, the red cells (6), leukocytes (7) which are trapped under the filter (5) and the platelets (4) and the plasma (3) that is, the useful cells which are on the upper part of the filter (5) are dissociated.

In the principle application of the invention, the filter (5) filtering the cells required for the solid plasma by dissociating the whole blood sample (2) is a polyester micro filter.

Incubation device (8) is used in the process of transforming the resulting plasma (3) and the liquid consisting of useful cells into solid plasma filling (9). Dissociated plasma (3) and platelet (4) are mixed and placed in the incubation device (8) and hold therein for 5 minutes at 70 ^e C, 7 minutes at 90 ^e C and 5 minutes at 5 ^e C.

The plasma (3) taken from said incubation device (8) is solid plasma filling (9) to be used as filling material.

After passing all stages it is a chemical-free filling material, since it is obtained by an autologous method, ready-to-use solid plasma filling (9) consisting of useful cells and plasma (3) present in human blood.